TG Therapeutics Swings to Quarterly Profit, Targets Higher Revenue in 2025

Dow Jones

03 Mar

By Robb M. Stewart

TG Therapeutics Is targeting a further jump in revenue this year after swinging to a profit in the latest quarter with higher sales of its flagship treatment for relapsing forms of multiple sclerosis.

The commercial-stage biopharmaceutical company swung to a profit of $23.3 million, or 15 cents a share, from a year-earlier loss of $14.4 million, or 10 cents a share. Analysts polled by FactSet had penciled in per-share earnings of 16 cents for the quarter.

Revenue more than doubled to $108.2 million from $44 million in the same period last year.

Product revenue for the quarter totaled $107.3 million, primarily reflecting $103.6 million in sales of Briumvi, a monoclonal antibody used as a multiple sclerosis treatment.

A monoclonal antibody is a type of protein that can bind to certain targets in the body. Multiple sclerosis is a long-lasting disease of the central nervous system.

TG Therapeutics is targeting global revenue in 2025 of about $540 million, including Briumvi U.S. product revenue of roughly $525 million. Analysts were expected revenue this year of $534.4 million, after the company recorded 2024 revenue of $329 million.

Full-year operating expense is expected to be about $300 million, excluding non-cash compensation, the company said.

Write to Robb M. Stewart at robb.stewart@wsj.com

(END) Dow Jones Newswires

March 03, 2025 07:47 ET (12:47 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2516382486"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2516382486\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2516382486?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-03 20:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2516382486","market":"us","top_or_hot":-1,"title":"TG Therapeutics Swings to Quarterly Profit, Targets Higher Revenue in 2025","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Robb M. Stewart \n</p>\n<pre>\n \n</pre>\n<p>\n  TG <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Is targeting a further jump in revenue this year after swinging to a profit in the latest quarter with higher sales of its flagship treatment for relapsing forms of multiple sclerosis. \n</p>\n<p>\n  The commercial-stage biopharmaceutical company swung to a profit of $23.3 million, or 15 cents a share, from a year-earlier loss of $14.4 million, or 10 cents a share. Analysts polled by FactSet had penciled in per-share earnings of 16 cents for the quarter. \n</p>\n<p>\n  Revenue more than doubled to $108.2 million from $44 million in the same period last year. \n</p>\n<p>\n  Product revenue for the quarter totaled $107.3 million, primarily reflecting $103.6 million in sales of Briumvi, a monoclonal antibody used as a multiple sclerosis treatment. \n</p>\n<p>\n  A monoclonal antibody is a type of protein that can bind to certain targets in the body. Multiple sclerosis is a long-lasting disease of the central nervous system. \n</p>\n<p>\n  TG Therapeutics is targeting global revenue in 2025 of about $540 million, including Briumvi U.S. product revenue of roughly $525 million. Analysts were expected revenue this year of $534.4 million, after the company recorded 2024 revenue of $329 million. \n</p>\n<p>\n  Full-year operating expense is expected to be about $300 million, excluding non-cash compensation, the company said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 03, 2025 07:47 ET (12:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TG Therapeutics Swings to Quarterly Profit, Targets Higher Revenue in 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTG Therapeutics Swings to Quarterly Profit, Targets Higher Revenue in 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-03 20:47</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Robb M. Stewart \n</p>\n<pre>\n \n</pre>\n<p>\n  TG <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Is targeting a further jump in revenue this year after swinging to a profit in the latest quarter with higher sales of its flagship treatment for relapsing forms of multiple sclerosis. \n</p>\n<p>\n  The commercial-stage biopharmaceutical company swung to a profit of $23.3 million, or 15 cents a share, from a year-earlier loss of $14.4 million, or 10 cents a share. Analysts polled by FactSet had penciled in per-share earnings of 16 cents for the quarter. \n</p>\n<p>\n  Revenue more than doubled to $108.2 million from $44 million in the same period last year. \n</p>\n<p>\n  Product revenue for the quarter totaled $107.3 million, primarily reflecting $103.6 million in sales of Briumvi, a monoclonal antibody used as a multiple sclerosis treatment. \n</p>\n<p>\n  A monoclonal antibody is a type of protein that can bind to certain targets in the body. Multiple sclerosis is a long-lasting disease of the central nervous system. \n</p>\n<p>\n  TG Therapeutics is targeting global revenue in 2025 of about $540 million, including Briumvi U.S. product revenue of roughly $525 million. Analysts were expected revenue this year of $534.4 million, after the company recorded 2024 revenue of $329 million. \n</p>\n<p>\n  Full-year operating expense is expected to be about $300 million, excluding non-cash compensation, the company said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 03, 2025 07:47 ET (12:47 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TG","symbol_name":"特里迪加","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2516382486","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516382486","pubTimestamp":1741006020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"TG Therapeutics Is targeting a further jump in revenue this year after swinging to a profit in the latest quarter with higher sales of its flagship treatment for relapsing forms of multiple sclerosis.The commercial-stage biopharmaceutical company swung to a profit of $23.3 million, or 15 cents a share, from a year-earlier loss of $14.4 million, or 10 cents a share. Analysts polled by FactSet had penciled in per-share earnings of 16 cents for the quarter.Revenue more than doubled to $108.2 million from $44 million in the same period last year.Product revenue for the quarter totaled $107.3 million, primarily reflecting $103.6 million in sales of Briumvi, a monoclonal antibody used as a multiple sclerosis treatment.A monoclonal antibody is a type of protein that can bind to certain targets in the body. Multiple sclerosis is a long-lasting disease of the central nervous system.TG Therapeutics is targeting global revenue in 2025 of about $540 million, including Briumvi U.S. product revenue ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TG":"特里迪加","TGTX":"TG Therapeutics Inc."},"translate_title":"TG Therapeutics实现季度盈利，目标是2025年实现更高收入","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TG":1,"TGTX":1},"content_text":"By Robb M. Stewart \n\n\n \n\n\n  TG Therapeutics Is targeting a further jump in revenue this year after swinging to a profit in the latest quarter with higher sales of its flagship treatment for relapsing forms of multiple sclerosis. \n\n\n  The commercial-stage biopharmaceutical company swung to a profit of $23.3 million, or 15 cents a share, from a year-earlier loss of $14.4 million, or 10 cents a share. Analysts polled by FactSet had penciled in per-share earnings of 16 cents for the quarter. \n\n\n  Revenue more than doubled to $108.2 million from $44 million in the same period last year. \n\n\n  Product revenue for the quarter totaled $107.3 million, primarily reflecting $103.6 million in sales of Briumvi, a monoclonal antibody used as a multiple sclerosis treatment. \n\n\n  A monoclonal antibody is a type of protein that can bind to certain targets in the body. Multiple sclerosis is a long-lasting disease of the central nervous system. \n\n\n  TG Therapeutics is targeting global revenue in 2025 of about $540 million, including Briumvi U.S. product revenue of roughly $525 million. Analysts were expected revenue this year of $534.4 million, after the company recorded 2024 revenue of $329 million. \n\n\n  Full-year operating expense is expected to be about $300 million, excluding non-cash compensation, the company said. \n\n\n \n\n\n  Write to Robb M. Stewart at robb.stewart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 03, 2025 07:47 ET (12:47 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}